Piracetam in Acute Stroke Study "PASS"


Phase 3 Results

Trial Description

To test the potential benefit of piracetam in the treatment of acute ischemic stroke.


  • Piracetam (Nootropil®)Drug
    Intervention Desc: Mechanism of action unknown; increases cerebral blood flow; inhibits platelet aggregation.

Trial Design

Randomized, double-blind parallel group design trial of 927 patients at 55 centers.

Patient Involvement

Patients received placebo or 12 g piracetam as an initial intravenous bolus followed by 12 g daily for 4 weeks and then 4.8 g daily for 8 weeks.


Type Measure Time Frame Safety Issue
Primary Neurologic outcome at 4 weeks as assessed by the Orgogozo scale.
Secondary Functional status at 12 weeks as measured by the Barthel Index.